1 / 9

Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum

Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum. Enterprise in 2013: An Important Role to play. Support a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society.

glenna
Download Presentation

Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vaccine Enterprise & CollaborationBill Snow, Director19 January 2013CHVI Afri-Can Forum

  2. Enterprise in 2013: An Important Role to play • Support a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society

  3. Enterprise in 2012: An Important Role to Play Support a global approach to the challenge of HIV vaccine R&D that transcends individual funders, countries, researchers, and civil society Coordination Collaboration Resource Optimization • Identify priority issues where collective effort is most effective • Engage current and new partners in the field • Identify new, unmet priority areas where additional resources are needed • Promote more efficient, faster ways for researchers and funders to share findings and avoid duplication of efforts • Convene scientific community to share and discuss information & data • Make best use of existing resources • Engage new funders and resources Knowledge Sharing • Share info on strategies, current & planned activities, and budget

  4. Priority Areas Identified • Clinical trial site capacity • Faster access to GMP product • Access to and comparability of multiple adjuvants • Industry expertise • Advancement criteria for efficacy trials • Tools to help funders’ maintain funding

More Related